neuro-ttransform: a study to evaluate the efficacy and safety of eplontersen (formerly known as ion-682884, ionis-ttr-lrx and akcea-ttr-lrx) in participants with hereditary transthyretin-mediated amyloid polyneuropathy

Conditions: Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Summary: the main objective of this study was to evaluate the efficacy of eplontersen as compared with the historical control of the placebo cohort in the neuro-ttr trial (nct01737398/2012-001831-30), in subjects with hereditary transthyretin-mediated amyloidosis polyneuropathy (hattr-pn). for more information, please visit http://www.neuro-ttransform.com/.

this study was a multicenter, open-label study in up to 168 participants, who were randomized to receive subcutaneous (sc) injections of either eplontersen once every 4 weeks or inotersen once a week. participants also received daily supplemental doses of the recommended daily allowance of vitamin a. participants included in the inotersen reference arm crossed over to eplontersen at week 37 after completing the week 35 assessments.

Eligibility criteria:
key inclusion criteria: 1. aged 18 to 82 years at the time of informed consent 2. females must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal or abstinent 3. males must be surgically sterile or, abstinent or, if engaged in sexual relations with a woman of child-bearing potential, the participant or the participantss non-pregnant female partner must be using a highly effective contraceptive method 4. diagnosis of hereditary transthyretin-mediated polyneuropathy as defined by meeting all 3 of the following: * stage 1 or stage 2 familial amyloid polyneuropathy (fap) or coutinho stage * documented genetic mutation in the ttr gene * symptoms and signs consistent with neuropathy associated with transthyretin amyloidosis, including neuropathy impairment score (nis) ≥ 10 and ≤ 130 key exclusion criteria: 1. clinically-significant (cs) abnormalities in medical history, screening laboratory results, physical or physical examination that would render a participants unsuitable for inclusion, including but not limited to abnormal safety labs 2. karnofsky performance status ≤ 50 3. other causes of sensorimotor or autonomic neuropathy (e.g., autoimmune disease), including uncontrolled diabetes 4. prior liver transplant or anticipated liver transplant within 1-yr of screening 5. new york heart association (nyha) functional classification of ≥ 3 6. acute coronary syndrome within 6 months of screening or major surgery within 3 months of screening 7. other types of amyloidosis 8. have any other conditions, which, in the opinion of the investigator or sponsor would make the participant unsuitable for inclusion, or could interfere with the participant participating in or completing the study 9. current treatment with any approved drug for hereditary ttr amyloidosis such as vyndaqel® / vyndamax™ (tafamidis), tegsedi™ (inotersen), onpattro™ (patisiran), off-label use of diflunisal or doxycycline, and tauroursodeoxycholic acid (tudca). if previously treated with vyndaqel® / vyndamax™, diflunisal or doxycycline, and tudca, must have discontinued treatment for at least 2 weeks prior to study day 1 10. previous treatment with tegsedi™ (inotersen) or onpattro™ (patisiran), or other oligonucleotide or rna therapeutic (including sirna)

Keywords: polyneuropathy amyloidosis attr ttr